Li; Dalin

Patent Applications and Registrations

Patent applications and USPTO patent grants for Li; Dalin.The latest application filed is for "methods of treating inflammatory bowel diseases that target ripk2".

Company Profile

7.5.10

Li; Dalin - Walnut CA
LI; Dalin - Los Angeles CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function Grant 11,434,296 - Shih , et al. September 6, 2	2022-09-06
Methods Of Treating Inflammatory Bowel Diseases That Target Ripk2 App 20220273665 - MCGOVERN; Dermot ; et al.	2022-09-01
Methods Of Predicting Non-response To Anti-tnf Treatment In Subjects With Inflammatory Bowel Disease App 20220153855 - McGOVERN; Dermot ; et al.	2022-05-19
Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease Grant 11,180,565 - McGovern , et al. November 23, 2	2021-11-23
Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) Grant 11,136,386 - Kruidenier , et al. October 5, 2	2021-10-05
Tl1a Patient Selection Methods, Systems, And Devices App 20210101988 - KRUIDENIER; Laurens ; et al.	2021-04-08
Methods And Systems For Characterizing Severe Crohn's Disease App 20210079473 - MCGOVERN; Dermot P. ; et al.	2021-03-18
Methods And Systems For Assessing Inflammatory Disease With Deep Learning App 20200342958 - MCGOVERN; Dermot P. ; et al.	2020-10-29
Methods Of Predicting Non-response To Anti-tnf Treatment In Subjects With Inflammatory Bowel Disease App 20200231690 - McGovern; Dermot ; et al.	2020-07-23
Mitigation And Reversal Of Fibrosis And Inflammation By Inhibition Of Tl1a Function And Related Signaling Pathways App 20200190203 - Shih; David Q. ; et al.	2020-06-18
Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway Grant 10,633,449 - Shih , et al.	2020-04-28
Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease Grant 10,626,180 - McGovern , et al.	2020-04-21
Diagnosis Of Inflammatory Bowel Disease Based On Genes App 20190194754 - MCGOVERN; Dermot P. ; et al.	2019-06-27
Methods Of Predicting Non-response To Anti-tnf Treatment In Subjects With Inflammatory Bowel Disease App 20180305459 - McGovern; Dermot ; et al.	2018-10-25
Mitigation And Reversal Of Fibrosis And Inflammation By Inhibition Of Tl1a Function And Related Signaling Pathways App 20160060335 - Shih; David Q. ; et al.	2016-03-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.